ClinicalTrials.Veeva

Menu

Evaluation of Biological Biomarkers Diagnostic of Toxoplasmosis Uveitis (BIOLUVE)

Grenoble Alpes University Hospital Center (CHU) logo

Grenoble Alpes University Hospital Center (CHU)

Status

Completed

Conditions

Subjects Clinically Suspected an Active Source of Toxoplasmosis Chorioretinitis Infection

Treatments

Other: Fluorescein angiography
Drug: Anti-toxoplasmosis treatment
Other: Puncture in anterior chamber
Drug: Anti-inflammatory treatments
Other: Dilated fundus examination
Biological: Toxoplasmosis serology

Study type

Interventional

Funder types

Other

Identifiers

NCT02843438
38RC09.014

Details and patient eligibility

About

Toxoplasmosis affects one to two newborn each 10000 births. Among them, 1 to 2 % develop learning disabilities or die, and 4 to 27 % develop a chorioretinitis sometimes leading to an amblyopia responsible for visual impairment. Toxoplasmosis uveitis affects too adults immunocompetent and immunodepressed who have had an acquired toxoplasmosis. Clinical diagnosis of ocular toxoplasmosis is more complicated in presence of posterior neuro-retinitis, inflammation of the papilla, uveitis without chorioretinitis, fuchs heterochromic iridocyclitis, scleritis, diffuse necrotizing or multifocal retinitis. In this situation biological markers diagnostic and prognostic of toxoplasmosis uveitis are useful.

Highly kept molecules (during evolution) like stress proteins (Hsp) are are found in the host and the pathogen and there can trigger a crossed immune response. Stress proteins haven't been explored yet, in the context of toxoplasmosis uveitis on humans.

The hypothesis is that Hsp70 and antibodies anti-Hsp70 are diagnostic and prognostic markers of ocular toxoplasmosis.

The goal is to evaluate diagnosis value of biological markers (Hsp70 and antibodies IgG anti-Hsp70) in toxoplasmosis uveitis.

Enrollment

72 patients

Sex

Ages

Under 18 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Age over 18 years
  • Subjects clinically suspected at least of one active source of toxoplasmosis chorioretinitis infection
  • Persons affiliated to national social security

Exclusion criteria

  • Pregnant, parturient or breastfeeding women
  • Persons deprived of liberty by judicial or administrative decision, person under legal protection
  • Refusal by a patient to do the PCA (anterior chamber puncture)
  • Patients whose following will be difficult or nonexistent

Trial design

Primary purpose

Screening

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

72 participants in 1 patient group

Subjects suspected of toxoplasmosis chorioretinitis infection
Other group
Description:
Subjects clinically suspected at least of one active source of toxoplasmosis chorioretinitis infection
Treatment:
Other: Fluorescein angiography
Biological: Toxoplasmosis serology
Drug: Anti-toxoplasmosis treatment
Other: Dilated fundus examination
Other: Puncture in anterior chamber
Drug: Anti-inflammatory treatments

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems